• Home
  • News & IR
  • News
Company News
디엑스앤브이엑스, 마이크로바이옴 기반 당뇨병 비만치료제 개발중
2022-10-24
Microbiome
마이크로바이옴은 '융합학문'…다양한 분야 전문가 협업 필수
2022-10-19
Microbiome
유사장기 ‘오가노이드’로 유산균 첫 발굴…염증성 장 질환 예방한다
2022-10-17
Company News
사업다각화 본궤도…유건상 한국바이오팜 대표 "마이크로바이옴 신제품 본격 출시"
2022-10-14
Company News
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx
2022-10-13
Company News
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx
2022-10-13
Anticancer
"고령 암환자도 면역항암제 치료 적극 고려해야"
2022-10-12
Company News
디엑스앤브이엑스, 170억원 규모 추가 투자유치 성공
2022-10-07
Diagnostics
KAIST, 염증성 장질환 진단 및 회복의 핵심효소 발견
2022-10-06
  1.   
  2. 26
  3. 27
  4. 28
  5. 29
  6. 30
  7. 31
  8. 32
  9.   
  • 10F, 173, Digital-ro, Geumcheon-gu, Seoul (Gasan-dong, Elysian)
  • Tel : 02-890-8700
  • IR Service : 02-6964-8770
  • Fax : 02-6964-8755

About Us

Goals & Promise

Leadership

Company History

IR

Notice & IR

Disclosure Information

Dx&Vx 2023 Award Impact

Contact

Private Policy Terms of Use twitter icon @dxvx_official
© 2024 Dx&Vx. All Rights Reserved.